COVID-19 is changing life as we know it. The firm handshake is now frowned upon, our temperatures are being checked before we walk into restaurants, a generally social human race has quickly become anything but, and the greatest minds in the world continue to search for ways to create a sense of normalcy as the result of vaccines and treatment options. That’s where Vitro Diagnostics (OTCMKTS: VODG) comes in.
VODG Has One Of The Best Cost Effective Models I’ve Seen In Biotech
Founded in 1986, Vitro Diagnostics develops stem-cell technology that’s used in the development of therapeutic options that range from anti-aging products to products designed to treat some of the world’s most debilitating conditions.
The technology alone is quite incredible, but the big story here, in my opinion, is how little cost is involved in the potential to make tens of millions of dollars in revenue.
In the stem cell therapy business, the cost associated with the production of these therapies is very high. However, VODG has found a way to essentially grow its stem cell product in a petri dish for a fraction of the cost.
Essentially, the company spends about $500,000 on clean rooms. Each room features six incubators that are used to allow the company’s allogeneic umbilical cord Mesenchymal Stem Cells (AlloRx Stem Cells® (“AlloRx”) to multiply.
This process happens so efficiently that the company is capable of generating five trillion stem cells from a single umbilical cord, giving the company an incredibly competitive advantage.
In fact, with a single clean room, the company is capable of generating 300 billion stem cells, which is enough to provide about 3,000 therapies. In terms of revenue, that works out to approximately $5 million annually from a single $500,000 clean room. These numbers are generally unseen in the biotechnology space.
What VODG Is Doing With Its Stem Cells
Throughout most of the company’s history, Vitro Diagnostics has been providing these stem cells to other companies for research purposes. In fact, the company’s high quality stem cells have been used in the development of therapeutic agents for MS, Crohn’s disease, osteoarthritis, heart disease, brain injury, autism, stroke, Parkinson’s disease, and Alzheimer’s disease. These AlloRx stem cells are even featured in anti-aging products.
In more recent years, however, VODG has been going through a bit of an evolution. Instead of simply supplying stem cells to other companies for the development and manufacturing of products, the company is climbing the food chain by developing its own high-quality stem cell therapies.
This Brings Us To The Company’s Work In COVID-19
As mentioned above, COVID-19 has caused so much change in our day-to-day lives, and we are all looking for options to get back to business as usual. For that to happen, we need effective treatments and vaccines on the market. VODG lives on the treatment side of the equation.
Stem cells are an incredible, naturally occurring tool. These cells have the ability to turn into any one of the 220 different types of cells that are floating around your body. They also have the ability to repair damaged cells and tissue in any part of the human body.
Essentially, stem cells are the cellular maintenance workers that keep the building that is our body standing up and functioning properly. If there’s something wrong, they likely have a way to fix it. This is where COVID-19 treatment comes in.
Stem cell therapies have already proven to be effective in the treatment of critically ill patients. In fact, a recent study surrounding umbilical cord stem cell therapies in China showed incredible promise. 17 critically ill COVID-19 patients were treated with umbilical-cord-derived stem cell therapies. All of these patients responded, quickly being taken off ventilators and breathing assistance and then rapidly discharged from the hospital.
In Israel, Pluristem (PSTI) reported the recovery of six patients treated with similar stem cells derived from the human placenta.
These results give VODG a strong base from which to build a case that their stem cells will be effective in the fight against COVID-19. In fact, the company has already treated one patient, which resulted in strong signals of safety, tolerability, and efficacy. Not to mention, Vitro has the ability to produce these treatments at a fraction of the cost, both in dollars and days, when compared to other processes being developed by competitors in the stem-cell space.
Having the ability to quickly manufacture relatively cost effective treatment options for severely ill COVID-19 patients is not just a competitive advantage, it’s a necessity in today’s pandemic-riddled healthcare ecosystem, and VODG seems to hold the key to these capabilities.
VItro Is Actively Pursuing COVID-19 Related Opportunities
It seems like every small biotechnology company is looking to use COVID-19 as its claim to fame. However, while many of these companies say that they’re working on options, few of them are actually taking action. Vitro Diagnostics is one of the companies that is performing.
Recently VODG submitted an Investigational New Drug application (IND) to the United States FDA. The goal of the IND is to seek permission to study the use of AlloRx stem cell therapy in humans as a potential treatment option for severely ill COVID-19 patients.
The company’s treatment has also been the subject of an emergency use authorization from the FDA surrounding the use of its AlloRx Stem Cells™ in the treatment of COVID-19 patients in critical condition, with the first patient already being treated.
Most recently, Vitro Diagnostics signed a Memorandum of Understanding (MOU) with Global Institute of Stem Cell Therapy and Research, or GIOSTAR. GIOSTAR is a leading stem-cell research institute in California.
Under the MOU, VODG and GIOSTAR will partner for a COVID-19 IND with the FDA using the company’s AlloRx Stem Cells™ in a clinical trial. This is a huge partnership for the company, as GIOSTAR is a world leader in stem-cell therapy with research and treatment centers around the globe.
As such, GIOSTAR will lead the way with regard to filing the IND application for the COVID-19 indication with the FDA while Vitro will provide AlloRx Stem Cells™ for the study that GIOSTAR will carry out.
Importantly, GIOSTAR has already obtained expedited compassionate-use authorization from the FDA for the use of stem-cell treatments in hospitalized patients with severe cases of COVID-19. Not only is this a massive milestone when it comes to the production of COVID-19 therapies, it is a massive personal milestone for Vitro, as the partnership will likely help in the company’s own work toward the authorization of the IND that it filed with the FDA about two months ago.
Vitro Beyond COVID-19
Vitro Diagnostics was here well before COVID-19 and will be well after. In fact, prior to the COVID-19 lockdown, the company saw increased revenues across all of its revenue categories for 13 consecutive quarters.
Indeed, for several years, VODG has been generating revenues through the sale of cell culture media, cell lines, and biomarker profiling, all of which have been used in the development of various therapies.
Aside from providing products and services to other companies, the company has also been seeing increased sales in its NutraVivo Stemulize dietary supplement. This supplement was designed to activate stem cells to migrate and produce new stem cells within the human body. It also activates anti-aging genes, improves cellular health, reduces inflammation, and promotes faster healing and recovery.
So, while COVID-19 is big, and VODG is quickly becoming a key player in the treatment of the condition, there is plenty more to look forward to, here, in terms of product and revenue growth.
The Bottom Line
The bottom line is that Vitro Diagnostics has several competitive advantages in the stem-cell therapy space. The company’s streamlined production process has created an opportunity that is one of the least cash flow intensive opportunities that I’ve ever seen.
Over the course of 13 consecutive quarters, this process has led to revenue growth and will likely continue to result in strong revenues for the company and its investors.
Now, as VODG steps into the COVID-19 space, it not only has a treatment option that’s viable and ready for study, but it is able to scale it’s production to meet the pandemic challenge.
No matter how you look at it, the work being done at Vitro is incredible, making VODG a stock that should not be ignored!
Get Free Alerts
Join our free mailing list to receive stock alerts!
This website/newsletter is owned, operated and edited by CNA Finance, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “CNA Finance” refers to CNA Finance, LLC. This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to publish information and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners do not own any shares in stocks mentioned unless stated in page disclosures. If we own any shares we will list the information relevant to the stock and number of shares here. CNA Finance, parent company to Alpha Stock News, receives payment to publish content and promote publicly traded companies. Pursuant to an agreement between CNA Finance and Vitro Diagnostics, CNA Finance has been hired for a period beginning on 6/26/20 and ending on 8/26/20 to conduct digital advertising and marketing and publicly disseminate information about VODG via Websites and Email. We have an agreement and have been paid six thousand dollars via check to cover the cost of content production and publication for the first month. We expect to receive another payment of six thousand dollars to cover costs of services for month two.This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated digital outreach efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of digital outreach marketing, which may end as soon as the marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct and Vitro Diagnostics has not approved the content of this site. Furthermore, CNA Finance often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.